Lupus Foundation of America

New research shows that the Renal Activity Index for Lupus could help predict treatment response in adults living with lupus nephritis

In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for ...
The Manila Times

European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard ...
GlobalData on MSN

EC approves Roche’s Gazyva to treat active lupus nephritis

Roche has received EC approval for its humanised monoclonal antibody Gazyva, in combination with mycophenolate mofetil (MMF).
Medical Dialogues

Roche Gazyva/Gazyvaro approved by European Commission for adults with active lupus nephritis

Basel: Roche has announced that the European Commission has approved Gazyva/Gazyvaro (obinutuzumab) in combination with ...
News-Medical.Net on MSN

University of Iowa research finds an effective therapy for rare kidney disease in children

A rare and life-threatening kidney disease in children finally has an effective therapy, thanks in large part to pioneering ...

Pegcetacoplan—the 'closest thing to a cure' for rare, severe kidney disease

A rare and life-threatening kidney disease in children finally has an effective therapy, thanks in large part to pioneering ...
TMCnet

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney ...
GEN - Genetic Engineering and Biotechnology News

C3 Glomerulopathy Treatment Breakthrough Found in Complement Inhibitor

Researchers describe pegcetacoplan, a new class of medication, as the “closest thing to a cure” for the rare, severe kidney disease C3 glomerulopathy.